• In July 2024, Roche completed the acquisition of LumiraDx's Point-of-Care technology, enhancing its diagnostics portfolio with a versatile platform capable of conducting multiple immunoassay and clinical chemistry tests on a single device.

• In 2023, Abbott Laboratories expanded its rapid lipid panel testing solutions, introducing advanced point-of-care devices that deliver quick and accurate cholesterol and triglyceride measurements, streamlining cardiovascular risk assessments.

In this report, the Lipid Testing Market has been segmented by Technology, Type of Test, Sample Type, Application and Geography.

Lipid Testing Market, Segmentation by Technology

The Lipid Testing Market has been segmented by Technology into Recent and Traditional.

Recent Technology

Recent advancements in lipid testing, such as enzymatic colorimetric assays, nuclear magnetic resonance (NMR), and liquid chromatography-mass spectrometry (LC-MS), are transforming the diagnostic landscape. These modern technologies now account for approximately 65% of the lipid testing market, thanks to their unmatched speed, accuracy, and reliability. Increased awareness of cardiovascular health and the need for early diagnosis have significantly boosted the adoption of these innovative testing solutions across hospitals and research laboratories.

Traditional Technology

Traditional lipid testing methods, including manual titration, gravimetric analysis, and older enzymatic techniques, continue to serve essential roles in cost-sensitive environments. While representing about 35% of the market, these methods are particularly prevalent in regions with limited access to modern diagnostic tools. Their continued usage is largely driven by their affordability and ease of implementation, even as the global trend shifts towards more advanced technologies.

Lipid Testing Market, Segmentation by Type of Test

The Lipid Testing Market has been segmented by Type of Test into Small-Dense LDL Testing, HDL Subclasses Testing, and Lipid Particle Size Testing.

Small-Dense LDL Testing

Small-dense LDL (sdLDL) testing has become a key tool in cardiovascular diagnostics, given the high atherogenic potential of these dense particles. Representing about 42% of the lipid testing market, sdLDL analysis is widely used for patients with diabetes, obesity, or metabolic syndrome. The growing need for targeted risk assessment is boosting the popularity of this specialized test across clinical settings.

HDL Subclasses Testing

HDL subclasses testing offers insights into the functional quality of HDL cholesterol rather than just its quantity. With a market share of around 28%, this segment is gaining attention as researchers and clinicians recognize that higher HDL levels do not always equate to lower cardiovascular risk. Its demand is particularly increasing in research institutions and specialized health centers.

Lipid Particle Size Testing

Lipid particle size testing provides a detailed evaluation of lipoprotein size distribution, enhancing cardiovascular risk profiling beyond basic lipid panels. Holding close to 30% of the lipid testing market, this method is essential in personalized healthcare approaches. It’s frequently adopted in preventive cardiology and by clinicians aiming for more accurate, individualized treatment plans.

Lipid Testing Market, Segmentation by Sample Type

The Lipid Testing Market has been segmented by Sample Type into Blood Samples, Plasma Samples, and Serum Samples.

Blood Samples

Blood samples dominate the lipid testing landscape, representing about 48% of the global market. Their straightforward collection process and broad applicability in both routine and advanced diagnostics make them the most preferred sample type. Blood-based lipid tests are critical in preventive healthcare and mass screening programs.

Plasma Samples

Plasma samples account for nearly 32% of lipid testing procedures, favored for their ability to deliver precise and stable results. By using anticoagulants, plasma tests allow for better separation and analysis of lipid components. They are commonly employed in research laboratories and settings that require high analytical accuracy.

Serum Samples

Serum samples comprise around 20% of the market and are increasingly used in specialized lipid profiling. The absence of clotting agents results in a purer sample matrix, enhancing the reliability of lipid measurements. Despite requiring more careful handling, serum-based testing is gaining popularity for its diagnostic clarity.

Lipid Testing Market, Segmentation by Application

The Lipid Testing Market has been segmented by Application into Food & Beverages and Food Ingredients.

Food & Beverages

In the food and beverage industry, lipid testing plays a vital role in ensuring product safety, nutritional consistency, and extended shelf life. This segment represents around 58% of the lipid testing market, largely influenced by stricter food regulations and health-conscious consumers. Regular lipid analysis helps manufacturers control fat content and detect oxidation or spoilage in processed products.

Food Ingredients

Lipid testing in food ingredients is essential for maintaining product integrity and meeting formulation specifications. Covering approximately 42% of the global market, this segment has grown due to increased demand for functional and clean-label ingredients. Lipid profiling supports quality assurance and regulatory compliance across diverse ingredient categories.

Lipid Testing Market, Segmentation by Geography

In this report, the Lipid Testing Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Lipid Testing Market Share (%), by Geographical Region

North America

North America remains the largest contributor to the lipid testing market, with an estimated 34% share. This growth is attributed to advanced healthcare systems, rising cases of cardiovascular conditions, and widespread use of diagnostic technologies. Government support and strong insurance coverage continue to fuel demand.

Europe

Europe commands roughly 27% of the lipid testing market, driven by aging demographics and well-established clinical practices. Strict food and health regulations and rising public focus on preventive diagnostics are key growth factors across nations like Germany, France, and the UK.

Asia Pacific

Asia Pacific is witnessing significant momentum, holding about 22% of the global market. Rapid urbanization, increased lifestyle-related diseases, and expanding healthcare infrastructure are pushing lipid testing adoption in countries such as India, China, and Japan.

Middle East and Africa

The Middle East and Africa region currently holds a 9% market share. Growth is being driven by rising healthcare investments and increasing awareness of chronic diseases. Although development is uneven, the demand for affordable diagnostic services is steadily increasing.

Latin America

Latin America makes up approximately 8% of the lipid testing market. Growing government initiatives and public health campaigns are boosting awareness and adoption, particularly in Brazil and Mexico. However, inconsistent access to modern healthcare facilities limits further expansion.

This report provides an in depth analysis of various factors that impact the dynamics of Lipid Testing Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers, Restraints and Opportunity Analysis

Drivers:

• Technological advancements
• Increasing prevalence of cardiovascular diseases
• Growing geriatric population
• Rising awareness programs

• Expansion in emerging markets - Expansion in emerging markets is a key driver of the Lipid Testing Market, propelled by the rising prevalence of cardiovascular diseases, diabetes, and obesity in developing regions. Increased urbanization, dietary changes, and sedentary lifestyles have contributed to higher incidences of lipid disorders, prompting healthcare systems to prioritize preventive diagnostics. As awareness of the importance of cholesterol monitoring grows, demand for reliable lipid testing services is accelerating across countries in Asia-Pacific, Latin America, and the Middle East.

  The development of healthcare infrastructure and expanded access to diagnostic technologies are further enabling the adoption of lipid testing in these markets. Government initiatives, insurance coverage expansion, and public health campaigns are encouraging routine screening and early detection, creating a favorable environment for diagnostic companies. As a result, the growing healthcare focus in emerging regions is playing a crucial role in driving market growth and broadening the global reach of lipid testing solutions.

Restraints:

• High cost of tests
• Limited awareness in developing regions
• Stringent regulatory approvals
• Complex reimbursement landscape

• Competitive pricing pressures - Competitive pricing pressures pose a significant restraint in the Lipid Testing Market, especially as the number of diagnostic service providers and test manufacturers continues to grow. Increased competition often leads to price reductions as companies attempt to gain or maintain market share. While this benefits end users through more affordable testing, it puts pressure on laboratories and diagnostic firms to cut operational costs and accept lower margins, which may hinder innovation and quality improvements over time.

  These pricing pressures are particularly challenging in price-sensitive regions where healthcare providers and government programs favor low-cost diagnostic solutions. Smaller players may struggle to stay profitable, while larger firms may be forced to reduce investments in R&D or scale back on premium service offerings. As a result, while pricing competition helps boost testing volumes, it can also slow down technological advancements and compromise long-term market sustainability.

Opportunities:

• Personalized medicine approaches
• Integration of AI
• Rise in preventive healthcare
• Focus on early diagnosis

• Patient-centric care models - The rise of patient-centric care models is opening new opportunities in the Lipid Testing Market, as healthcare systems shift focus from treatment to prevention and personalized monitoring. These care models emphasize empowering patients to actively manage their health through regular testing, lifestyle changes, and informed decision-making. Lipid testing plays a vital role in this paradigm by providing essential data on cholesterol levels and cardiovascular risk factors, allowing individuals and clinicians to take preventive actions before conditions become critical.

  With advancements in home-based diagnostic devices and digital health platforms, patients can now access lipid testing more conveniently than ever. This increased accessibility supports continuous health monitoring and enables early interventions, reducing the long-term costs associated with untreated lipid disorders. As consumers demand more transparency and control over their medical information, lipid testing integrated into patient-centered health plans is becoming a preferred option for proactive disease management.

  Healthcare providers are also adopting value-based care models that rely on routine monitoring to improve outcomes and reduce hospital admissions. In this context, lipid testing becomes a critical component of chronic disease management programs, particularly for populations at risk of heart disease, stroke, or metabolic syndrome. This alignment between patient-centered strategies and diagnostic innovation enhances both patient engagement and provider efficiency.

  As patient-centric care continues to evolve, diagnostic manufacturers and service providers have an opportunity to develop customized testing solutions, including wearable technologies, mobile health integrations, and personalized risk assessments. These innovations will not only expand the reach of lipid testing but also redefine its role in promoting long-term cardiovascular health across diverse global populations.

Key players in Lipid Testing Market include:

• Abbott Laboratories
• F. Hoffmann-La Roche Ltd.
• Siemens Healthineers AG
• Thermo Fisher Scientific Inc.
• Nova Biomedical Corporation
• SD Biosensor, Inc.
• Menarini Group
• Callegari Srl
• Sinocare Inc.
• MiCo BioMed

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Market Share Analysis
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis